Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Decreases By 34.4%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 25,600 shares, a drop of 34.4% from the November 30th total of 39,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.1% of the company’s shares are short sold.

ZyVersa Therapeutics Stock Down 6.5 %

NASDAQ ZVSA opened at $1.15 on Monday. ZyVersa Therapeutics has a 1-year low of $0.98 and a 1-year high of $25.00. The firm’s fifty day simple moving average is $1.38 and its 200-day simple moving average is $2.59.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.